GovChime
Notice ID: 22c0481ab5c54b4d8274645121563f56Combined Synopsis/Solicitation

Vaccines for Children 2021

Archived on February 19, 2021. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
6:00 PM UTC−05:00
Posted
February 1, 2021
Notice type
Combined Synopsis/Solicitation
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Health and Human ServicesCENTERS FOR DISEASE CONTROL AND PREVENTION

Notice details

Office
CDC NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES
Last updated
Sep 9, 2025

Identifiers

Solicitation number
75D301-21-R-71773
Notice ID
22c0481ab5c54b4d8274645121563f56

Description

The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) requires the award of one or more indefinite quantity, indefinite delivery contracts for the purchase of the following pediatric vaccines and estimated quantities manufactured under a current establishment and product license issued by the U.S. Food and Drug Administration: ITEM SUPPLIES / SERVICES QTY / UNIT 1.DTaP vaccine: Min. Shelf Life: 12 Months Fed. Excise Tax: $2.25 per dose Maximum: 6.5M Doses Minimum: 100 Doses 2.DTaP/Hep B/IPV vaccine: Min. Shelf Life: 12 Months Fed. Excise Tax: $3.75 per dose Maximum: 5.38M Doses Minimum: 100 Doses 3.DTaP-IPV Vaccine: Min. Shelf Life: 12 months Fed. Excise Tax: $3.00 per dose Maximum: 3.5M Doses Minimum: 100 Doses 4.DTaP-IP-HI Vaccine: Min. Shelf Life: 12 months Fed. Excise Tax: $3.75 per dose Maximum: 7.5M Doses Minimum. 100 Doses 5.E-IPV vaccine: Min. Shelf Life: 12 Months Fed. Excise Tax: $0.75 per dose Maximum: 4M Doses Minimum: 100 Doses 6.Hepatitis A (pediatric) vaccine Min. Shelf Life: 12 Months Fed. Excise Tax: $0.75 per dose Maximum: 8.5M Doses Minimum: 100 Doses 7.Hepatitis A&B (Age 18 only) vaccine Min. Shelf Life: 12 Months Fed. Excise Tax: $1.50 per dose Maximum: 100,000 Doses Minimum: 100 Doses 8.Hepatitis B (pediatric/adol.) vaccine Min. Shelf Life: 12 Months Fed. Excise Tax: $0.75 per dose Maximum: 7.7M Doses Minimum: 100 Doses 9.Hib vaccine Min. Shelf Life: 12 Months Fed. Excise Tax: $0.75 per dose Maximum: 8M Doses Minimum: 100 Doses 10.Human Papillomavirus types Vaccine, Recombinant Min. Shelf Life: 12 Months Fed. Excise Tax: $0.75 per dose Maximum: 9M Doses Minimum: 100 Doses 11.Measles, Mumps & Rubella (MMR) vaccine Min. Shelf Life: 12 Months Fed. Excise Tax: $2.25 per dose Maximum: 8M Doses Minimum: 100 Doses 12.Meningococcal Conjugate (MCV4) vaccine Min. Shelf Life: 12 Months Fed. Excise Tax: $0.75 per dose Maximum: 6.5M Doses Minimum: 100 Doses 13. Pneumococcal Conjugate vaccine (13 Valent) Min. Shelf Life: 12 Months Fed. Excise Tax: $0.75 per dose Maximum: 13M Doses Minimum: 100 Doses 14.Pneumococcal (23 Valent) Polysaccharide Vaccine Min. Shelf Life: 12 Months Fed. Excise Tax: N/A Maximum: 350K Doses Minimum: 100 Doses 15.Rotavirus vaccine Min. Shelf Life: 12 Months Fed. Excise Tax: $0.75 per dose Maximum: 7M Doses Minimum: 100 Doses 16.Tetanus and Diphtheria (Td) vaccine Min. Shelf Life: 12 Months Fed. Excise Tax: $1.50 per dose Maximum: 750,000 Doses Minimum: 100 Doses 17.Tdap vaccine Min. Shelf Life: 12 Months Fed. Excise Tax: $2.25 per dose Maximum: 5.5M Doses Minimum: 100 Doses 18.Varicella vaccine Min. Shelf Life: 12 Months Fed. Excise Tax: $0.75 per dose Maximum: 10M Doses Minimum: 10 Doses 19.Measles, Mumps & Rubella (MMR-V) and Varicella vaccine Min. Shelf Life: 12 Months Fed. Excise Tax: $3.00 per dose Maximum: 3.3M Doses Minimum: 10 Doses 20.Serogroup B Meningococcal Min. Shelf Life: 12 Months Fed. Excise Tax: $0.75 per dose Maximum: 2.5M Doses Minimum: 100 Doses The vaccines awarded under these contracts will be purchased for and by NCIRD's Immunization Awardees to support pediatric immunization programs as provided under Section 317(j) of the Public Health Service Act and Vaccine for Children (VFC) program, established pursuant to Section 13631 of the Omnibus Budget Reconciliation Act of 1993 (OBRA '93). This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items. Vaccines shall be shipped F.O.B. Destination to the 50 states and U.S. Territories. The period of performance shall be 4/1/2021 3/31/2022. Any questions regarding this notice shall be submitted in writing to Christina McMichael at wpn6@cdc.gov. Telephone inquiries will not be honored. Questions and Answers: 1) Can we propose other vaccines? Answer: Yes, if the vaccine is FDA and ACIP approved.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75D301-21-R-71773
  1. Combined Synopsis
  1. 2×
    Combined SynopsisCurrentJan 21, 2021

    Vaccines for Children 2021

    Notice 22c0481ab5c54b4d8274645121563f56 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Fluzone and Flublok Influenza Vaccines for the 2026-2027 Flu season. The vaccine is required to immunize embassy immunocompromised family members.
83%
Sole Source / J&AOpen
PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue a Request for Proposal (RFP) 36E79726R0035 for an unrestrictive procurement for the Influenza Virus Vaccine for the Department of Veterans Affairs (VA) to include State Veteran Homes option 2 (SVH2 s), Bureau of Prisons (BOP), Indian Health Service (IHS), and Captain James A. Lovell Federal Health Care Center (FHCC) for the 2027-2028 Influenza Season. Evaluation and award will be made by solicitation line item for VA, BOP, IHS, and FHCC requirements. Offerors are not required to submit an offer for every line item; however, the offeror must offer the full quantity for each line item offered. Additionally, all offered line items for a single presentation must be offered at the same unit price. Please note that the final offered price must include the Cost Recovery Fee (CRF) and Federal Excise Tax (FET). Orders will be placed by and delivered to VA, SVH2, BOP, and IHS facilities throughout the United States, the Philippines and Puerto Rico. The contractor(s) will be required to deliver the vaccine Free On Board (FOB) Destination to Government facilities within the U.S., Philippines, and Puerto Rico. The first shipment of product ordered must be at least 50% of each individual facility s ordered quantity and must be delivered between August 15, 2027, and September 15, 2027. The second shipment must be for the remaining individual facility s entire ordered quantity and must be delivered between September 16, 2027, and October 15, 2027. FHCC shall receive 100% of the awarded quantities between August 15, 2027 and September 15, 2027. Solicitation number 36E79726R0035 is estimated to be electronically issued in commercial item format in accordance with FAR Part 12 on or about September 8, 2026, with a closing date of September 24, 2026. ESTIMATED ANNUAL REQUIREMENTS BY AGENCY PRESENTATION DESCRIPTION PACKAGE TYPE VA EST ANNUAL USAGE BOP EST ANNUAL USAGE IHS EST ANNUAL USAGE FHCC EST ANNUAL USAGE TOTAL ESTIMATED ANNUAL USAGE 1 Influenza Virus Vaccine: Pre-filled single dose syringes with plunger and Luer lock needle attachment, Trivalent or Quadrivalent; 2027-2028 influenza season; latex and preservative free: for persons 36 months. SYRINGE (Box of 10) 120,000 6,129 27,200 550 153,879 2 I Influenza Virus Vaccine: Pre-filled single dose syringe with plunger and Luer lock needle attachment, Trivalent or Quadrivalent; 2027-2028 influenza season; latex and preservative free; must be specifically designed for persons 65 years and older as approved by the FDA. SYRINGE (Box of 10) 110,000 280 11,000 400 121,680 3 Influenza Virus Vaccine: Pre-filled single dose syringe with plunger and Luer lock needle attachment, Trivalent or Quadrivalent; 2027-2028 influenza season. Must be split virus vaccine (subvirion or purified surface antigen) that has been FDA approved and labeled with indications for administration to children 6 months - 35 months of age (pediatric), latex and preservative free. SYRINGE (Box of 10) 0 0 1,000 0 1,000 The final vaccine presentation for each line item (Trivalent or Quadrivalent) shall be based on recommendations issued by WHO. If WHO recommends both Trivalent and Quadrivalent influenza strain presentations, and both are commercially available from the offeror or contract awardee, the Trivalent presentation shall be required.
82%
Pre-Solicitation09/08/2026
Annual delivery order issued on a sole-source basis from the Department of Veteran’s Affairs Glaxosmith Kline federal supply schedule for pharmaceuticals and vaccines. The specific contract number is 36F79722D0178. The delivery order will be for proprietary Fluarix and Flulaval Influenza vaccines.
73%
Sole Source / J&AOpen
Sources-Sought Notice The Indian Health Service, Crownpoint Service Unit is issuing this sources-sought notice (SSN) to identify capable Indian-owned, economic enterprises – large (IEE) or small (ISBEE) – that can provide A Blanket Purchase Agreement for IV fluids on an “As Needed Basis” for the General Services Department. This will be issued as a Base Year plus (4) Option Years. Other capable firms are also invited to respond to this SSN. The Contracting Officer will consider responses for Buy Indian Act (25 U.S.C. 47) opportunities first, then for set aside programs under the Small Business Act (41 U.S.C. 3104). The applicable North American Industry Classification System (NAICS) code assigned to this requirement is 325412- Pharmaceutical Preparation Manufacturing with a small business size standard of 1300 Employees. THIS IS NOT A SOLICITATION. Information collected from this notice is purely for market research only and will be used to determine the contracting office’s acquisition strategy including competition, set asides, and locating Indian-owned economic enterprises. Submission of any information in response to this market survey is purely voluntary. The government assumes no financial responsibility for any costs incurred in response to this request for information. In accordance with FAR 4.203-1(b), offerors and quoters must be registered in System for Award Management at SAM.gov, at the time an offer or quotation is submitted and at time of award. Submission Instructions: Interested parties who consider themselves qualified to perform the above-listed services are invited to submit a response to this notice by November 23, 2026, 8:00am MT to Arlynda Largo at Arlynda.largo@ihs.gov with the subject line “SSN-CPSU-1533180- BPA for IV Fluids on an “As Needed Basis”. Your submission must include the following information, at a minimum: 1. Company Profile that includes: UEI, Name and Address, Primary POC information, business size and type of ownership, socio-economic status/participation such as 8(a), WOSB/EDWOSB, SDVOSB and HUBZone, identification of Native American ownership, SAM.gov representations and certifications, and other related documentation. 2. A brief statement of the company’s capability that relates to the described government requirement. Additional demonstration of capability may include current and past performance history for the same or similar requirement, established contracts such as GSA or VA Schedule, etc. 3. Indian-owned Small Business Economic Enterprises (ISBEEs) and Indian-owned Economic Enterprises (IEEs) must also submit a completed IHS IEE Representation Form (attached) in accordance with HHSAR 326.606-1(b).
63%
Market Research11/23/2026
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
63%
Pre-Solicitation11/11/2026

Additional Details

Solicitation Number

75D301-21-R-71773

Archive Date

Feb 19, 2021

Office Address

Atlanta, GA, 30333